Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Follow up Local Registry Study of Kymriah in South Korea
Sponsor: Novartis Pharmaceuticals
Summary
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.
Official title: A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea
Key Details
Gender
All
Age Range
0 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2025-03-12
Completion Date
2039-12-30
Last Updated
2026-02-23
Healthy Volunteers
No
Interventions
Tisagenlecleucel
This is an observational study. There is no treatment allocation. The decision to initiate tisagenlecleucel will be based solely on clinical judgement.
Locations (16)
Novartis Investigative Site
Bundang Gu, Gyeonggi-do, South Korea
Novartis Investigative Site
Seongnam-si, Gyeonggi-do, South Korea
Novartis Investigative Site
Gyeonggi-do, Korea, South Korea
Novartis Investigative Site
Incheon, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Seoul, South Korea
Novartis Investigative Site
Seoul, Seoul, South Korea
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Jeollanam, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Ulsan, South Korea